NHS England: Pride, pressures, possibilities and patient-centric care
By: Peter Rutherford, MD, PhD | July 23, 2015
Pride and pressure
In 2013, the UK’s NHS celebrated its 65th anniversary, and the core principles are still to:
Steps towards patient-centric medicine
According to Stevens, over the next period NHS England will focus on a number of key areas, including cancer, mental health, and maternity and learning disability services. These will move the emphasis from long-term hospital-based care to community-based primary care, and will support the integration of health and social care. This requires a shift towards patient-centric medicine, and greater investment into primary care and patient education. The result will be to empower patients to make choices about treatment and work together with healthcare professionals in order to improve their health and their disease management.
Where biopharma can help
As a tax-based healthcare service, the NHS has limited budgets to supply treatments for a growing and aging population. Biopharma companies can help to improve access by working in collaboration with healthcare providers on a more local level. As an example, companies can work together in partnership with clinical commissioning groups (CCGs) to tailor local service design and purchasing at a local, or even patient level. While still remaining within the overall NHS England strategic agenda, this will effectively create an individualized commissioning process that could improve access for patients, and especially those with the greatest level of need.
Mapping pathways and redesigning service access can allow patients to access services more easily or more cost-effectively, with better outcomes, as well as freeing up money to spend on drugs, and improving the experience for both staff and patients. You can read a full case study here.
Getting to the goal
While individualized commissioning and patient-centric medicine is the ideal, it will take time to put the networks of communication in place between all the stakeholders, and provide the level of evidence of clinical and cost-effectiveness that is tailored to each area of local need. However, some biopharma companies are already taking the lead to improve access for patients across many therapeutic areas, including cancer, and by working together the outcomes can only improve.
To learn more about our thinking and to understand the way Quintiles approach supporting the NHS to improve access for patients, we recommend you read: